论文部分内容阅读
在稳定型冠心病患者中,初期治疗方案选择行经皮冠状动脉介入治疗(PCI)的同时进行强化药物治疗以及对生活方式的干预,是否比单独进行药物治疗能更好地降低心血管事件发生的风险尚不清楚。为此,由美国退伍军人事务部和加拿大卫生研究院合作进行了一项随机对照研究,即血管再通和强效药物治疗临床结果评估(COURAGE),结果表明在稳定型冠心病中,PCI 加最佳药物治疗,并不比单独最佳药物治疗效果更好。研究者在美国心脏病学会第56届科学年会上报告了该结果,并发表在《新英格兰医学杂志》上(N Engl J Med,2007,356:1503—1516)。COURAGE 研究由美国纽约州水牛城市总医院的William Boden 医学博士领导,收入来自美国和加拿大50个研究中心的2287例有心肌缺血客观证据以及确诊冠状动脉心脏病的患者。参加 COURAGE 者大多为白种人,男性,平
In patients with stable coronary artery disease, initial treatment options for percutaneous coronary intervention (PCI) in combination with intensive medical therapy and lifestyle intervention are better than single drug therapy to reduce cardiovascular events The risk is not clear. To this end, the United States Department of Veterans Affairs and the Canadian Institute of Health conducted a randomized controlled study of recanalization and potent drug therapy clinical outcome evaluation (COURAGE), the results show that in stable coronary heart disease, PCI plus The best medication is no better than the best medication alone. The researchers report the results at the 56th Annual Scientific Meeting of the American College of Cardiology and in the New England Journal of Medicine (N Engl J Med, 2007, 356: 1503-1516). The COURAGE study was led by William Boden, MD, of the Buffalo General Hospital in New York, and received 2287 patients with objective evidence of myocardial ischemia and patients diagnosed with coronary heart disease from 50 research centers in the United States and Canada. COURAGE to participate in mostly white, male, flat